RESUMEN
BACKGROUND/OBJECTIVES: The primary aim of this study was to analyse and evaluate the impact of different local treatments on the pattern of relapse in children with primary head and neck non-parameningeal (HNnPM) rhabdomyosarcoma (RMS), treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS2005 study. The secondary aim was to assess whether current risk stratification is valid for this specific site. DESIGN/METHODS: This study includes all patients with localised HNnPM RMS enrolled in the RMS2005 study between 2005 and 2016. Treatment comprised chemotherapy adapted to risk group, with local surgery and/or radiation therapy. The main outcome measures were event-free survival (EFS) and overall survival (OS). RESULTS: A total of 165 patients were identified; the median age was 6.4 years (range, 0.1-25). The most common tumour sites were cheek/chin (22%) and nasal ala/nasolabial fold (20%). Histology was unfavourable for 40%, and regional nodal involvement present in 26%. Local therapy included surgery (58%) and/or radiotherapy (72%) to primary tumour and/or regional lymph nodes. After a median follow-up of 66 months (range, 6-158), 42 patients experienced an event, and 17 are still alive. Tumour events were frequent in oral primary (36%), parotid site (26%), cheek/chin (24%), and nasal ala/nasolabial fold (24%) and included locoregional failure in 84% of cases. The 5-year EFS and OS were 75% (95% confidence interval [CI]: 67.3-81.2) and 84.9% (95% CI: 77.5-89.7), respectively. Favourable histology was associated with a better EFS (82.3% versus 64.6%; p = 0.02) and nodal spread with a worse OS (88.6% versus 76.1%; p = 0.04). Different sublocations within the HNnPM primary did not have significant impact on outcome. CONCLUSION: Locoregional relapse/progression is the main tumour failure event in this site. Despite frequent unfavourable risk factors, HNnPM RMS remains a favourable location in the context of a risk-adapted strategy.
Asunto(s)
Neoplasias de Cabeza y Cuello/terapia , Recurrencia Local de Neoplasia , Rabdomiosarcoma/terapia , Adolescente , Adulto , Factores de Edad , Argentina , Brasil , Niño , Preescolar , Progresión de la Enfermedad , Europa (Continente) , Femenino , Neoplasias de Cabeza y Cuello/mortalidad , Neoplasias de Cabeza y Cuello/patología , Humanos , Lactante , Israel , Metástasis Linfática , Masculino , Supervivencia sin Progresión , Estudios Prospectivos , Rabdomiosarcoma/mortalidad , Rabdomiosarcoma/secundario , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo , Adulto JovenRESUMEN
The incidence of central nervous system (CNS) involvement in patients with rhabdomyosarcoma (RMS) is low, and the outcome is dismal. We present a single institution analysis of CNS involvement of pediatric RMS. In 59 patients, the prevalence of CNS involvement was 11.9% (7 patients), higher than prior reports. Of the 6 deaths from disease, all had rapid progression, with a median survival of 14 days. The higher incidence could be secondary to treatment modifications or more sensitive detection. These findings are useful for decisions at the time of CNS involvement and could lead to modifications for future RMS clinical trials.
Asunto(s)
Neoplasias del Sistema Nervioso Central , Rabdomiosarcoma , Adolescente , Adulto , Neoplasias del Sistema Nervioso Central/mortalidad , Neoplasias del Sistema Nervioso Central/terapia , Niño , Preescolar , Supervivencia sin Enfermedad , Femenino , Humanos , Masculino , Prevalencia , Estudios Retrospectivos , Rabdomiosarcoma/mortalidad , Rabdomiosarcoma/terapia , Tasa de SupervivenciaRESUMEN
BACKGROUND: Pretreatment neutrophil-to-lymphocyte ratio (NLR) and absolute lymphocyte count (ALC) recovery have been shown to be associated with prognosis in several types of cancer in adults. However, evidence in pediatric cancer is scarce. The aim of our study was to evaluate whether pretreatment NLR and lymphocyte recovery are prognostic factors in pediatric sarcomas. MATERIALS AND METHODS: Study participants were identified from a retrospective cohort of 100 children with osteosarcoma (n=55), rhabdomyosarcoma (n=22), and Ewing sarcoma (n=23). Data for the hematological variables were obtained from medical records and analyzed with other known prognostic factors in univariate and multivariate analyses. RESULTS: In multivariate analysis, NLR>2 was an independent prognostic factor for OS in patients with osteosarcoma (hazard ratio [HR], 2.27, 95% confidence interval [CI], 1.07-5.30; P=0.046) along with metastatic disease and poor histologic response; as well as in patients with rhabdomyosarcoma (HR, 4.76, 95% CI, 1.01-22.24; P=0.0237) along with metastatic disease and risk group. ALC recovery correlated for inferior OS in osteosarcoma (HR, 3.34, 95% CI, 1.37-8.12; P=0.008) and rhabdomyosarcoma (HR, 3.89; 95% CI, 1.01-14.89; P=0.0338). CONCLUSIONS: Our study confirms that NLR and ALC recovery are independent prognostic factors for pediatric sarcomas, implying an important role of immune system in survival. Clinical utility of these prognostic biomarkers should be validated in larger pediatric studies.
Asunto(s)
Linfocitos/patología , Neutrófilos/patología , Pronóstico , Sarcoma/diagnóstico , Biomarcadores , Niño , Estudios de Cohortes , Femenino , Humanos , Recuento de Leucocitos , Masculino , Metástasis de la Neoplasia , Osteosarcoma/tratamiento farmacológico , Osteosarcoma/mortalidad , Estudios Retrospectivos , Rabdomiosarcoma/tratamiento farmacológico , Rabdomiosarcoma/mortalidad , Sarcoma/sangre , Sarcoma/mortalidad , Sarcoma/patología , Sarcoma de Ewing/tratamiento farmacológico , Sarcoma de Ewing/mortalidad , Tasa de SupervivenciaRESUMEN
OBJECTIVES: To compare 3 methods of dimensional assessment, with particular attention to a new software assisted method of volume calculation, in soft tissue sarcoma, and to investigate the interobserver agreement and the intermethod agreement in chemotherapy response classification and resultant clinical repercussions. STUDY DESIGN: We studied 34 pediatric patients with nonmetastatic soft tissue sarcoma who had undergone only diagnostic biopsy. Tumor size was measured both at diagnosis and after induction chemotherapy by 3 observers and using 3 measurement methods: maximum axis (1 diameter), estimated volume (3 diameters), and computed volume (software-assisted volume calculation). We used overall concordance correlation coefficient and Bland-Altman statistical methods to assess interobserver agreement and overall concordance correlation coefficient and the κ Cohen coefficient to assess intermethod agreement. RESULTS: According to overall concordance correlation coefficient, the interobserver agreement was very high for each method, with a slight superiority of the software assisted method; this agreement was not confirmed in Bland-Altman plots for maximum axis and estimated volume methods. According to kappa coefficients, the intermethod agreement in chemotherapy response evaluation was poor. CONCLUSIONS: Computed volume was the most accurate method in soft tissue sarcoma tumor size assessment. One- and 3-dimensional methods are not concordant in chemotherapy response classification. In particular, the maximum axis method underestimates chemotherapy response and can lead to switching the chemotherapy regimen erroneously.
Asunto(s)
Interpretación de Imagen Asistida por Computador , Imagenología Tridimensional , Imagen por Resonancia Magnética/métodos , Sarcoma/diagnóstico por imagen , Sarcoma/tratamiento farmacológico , Tomografía Computarizada por Rayos X/métodos , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Niño , Preescolar , Estudios de Cohortes , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Lactante , Masculino , Variaciones Dependientes del Observador , Sistema de Registros , Estudios Retrospectivos , Rabdomiosarcoma/diagnóstico por imagen , Rabdomiosarcoma/tratamiento farmacológico , Rabdomiosarcoma/mortalidad , Medición de Riesgo , Sarcoma/mortalidad , Análisis de Supervivencia , Resultado del Tratamiento , Carga TumoralRESUMEN
BACKGROUND: Children with cancer in middle-income countries have inferior outcomes compared with similar children in high-income countries. The magnitude and drivers of this survival gap are not well understood. In the current report, the authors sought to describe patterns of clinical presentation, magnitude of treatment abandonment, and survival in children with sarcoma in Central America. METHODS: A retrospective review was conducted of hospital-based registries from national pediatric oncology referral centers. Patients with newly diagnosed osteosarcoma, Ewing sarcoma, rhabdomyosarcoma (RMS), and soft tissue sarcoma (STS) between January 1, 2000 and December 31, 2009 were included. Survival analyses were performed first using standard definitions of overall survival (OS) and event-free survival (EFS) and then with abandonment included as an event (abandonment-sensitive OS and abandonment-sensitive EFS). RESULTS: In total, 785 new cases of pediatric sarcoma were reported (264 diagnoses of osteosarcoma, 175 diagnoses of Ewing sarcoma, 240 diagnoses of RMS, and 106 diagnoses of STS). The rate of metastatic disease at presentation was high (osteosarcoma, 38%; Ewing sarcoma, 39%; RMS, 29%; and STS, 21%). The treatment abandonment rate also was high, particularly among patients with extremity bone sarcomas (osteosarcoma, 30%; Ewing sarcoma, 15%; RMS, 25%; and STS, 15%). Of 559 patients who experienced a first event, 59% had either recurrent or progressive disease. The 4-year OS rate (±standard error) was 40% ± 3%, and the EFS rate was 30% ± 2%; however, these rates decreased further to 31% ± 2% and 24% ± 2%, respectively, when abandonment was taken into account. CONCLUSIONS: The current results indicated that high rates of metastases and treatment abandonment and difficulty with upfront treatment effectiveness are important contributors to the poor survival of children with pediatric sarcomas in Central America. Initiatives for early diagnosis, psychosocial support, quality improvement, and multidisciplinary care are warranted to improve outcomes.
Asunto(s)
Sarcoma/mortalidad , Sarcoma/terapia , América Central , Niño , Estudios de Cohortes , Femenino , Humanos , Masculino , Osteosarcoma/mortalidad , Osteosarcoma/terapia , Cooperación del Paciente/estadística & datos numéricos , Sistema de Registros , Rabdomiosarcoma/mortalidad , Rabdomiosarcoma/terapia , Sarcoma/patología , Sarcoma de Ewing/mortalidad , Sarcoma de Ewing/terapia , Análisis de SupervivenciaRESUMEN
UNLABELLED: Rhabdomyosarcoma (RMS) is a malignant tumor of soft tissues, more common in childhood, mainly located in the head and neck. It presents varied clinical and biological behavior and requires individualized management. AIM: To describe information on patients with head and neck RMS diagnosed and treated in a hospital, and to compare them to results in the literature. STUDY DESIGN: Descriptive and retrospective. MATERIALS AND METHODS: A retrospective analysis of data from 24 patients with head and neck rhabdomyosarcoma diagnosed and treated in a hospital from 1994 to 2008. RESULTS: The mean age was 7.79 years. According to gender, 54.17 % were males and 45.83 % were female. All patients underwent chemotherapy (CT), 62.5% of them also underwent radiotherapy (RT) and 16.67% were submitted to surgery. Of the 24 patients, 8 (33.3%) died, 6 (25%) were found free of neoplasia and 2 (8.3%) experienced tumor recurrence. CONCLUSION: The RMS of the head and neck often presents with nonspecific symptoms. Individualized multimodal therapy should be performed for these patients, including surgery, chemotherapy and radiotherapy.
Asunto(s)
Neoplasias de Cabeza y Cuello , Rabdomiosarcoma , Adolescente , Adulto , Niño , Preescolar , Terapia Combinada/métodos , Supervivencia sin Enfermedad , Femenino , Neoplasias de Cabeza y Cuello/diagnóstico , Neoplasias de Cabeza y Cuello/mortalidad , Neoplasias de Cabeza y Cuello/terapia , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Rabdomiosarcoma/diagnóstico , Rabdomiosarcoma/mortalidad , Rabdomiosarcoma/terapia , Adulto JovenRESUMEN
O rabdomiossarcoma (RMS) é o tumor maligno de partes moles mais comum na infância, localizando-se principalmente na cabeça e pescoço. Apresenta comportamento clínico-biológico variado, devendo receber terapia individualizada. OBJETIVO: Descrever os dados de pacientes portadores de RMS de cabeça e pescoço diagnosticados e tratados em um hospital comparando-os aos da literatura. Forma de Estudo: Descritivo retrospectivo. MATERIAL E MÉTODO: Análise retrospectiva de dados de prontuários de 24 pacientes portadores de RMS de cabeça e pescoço diagnosticados e tratados em um hospital no período de 1994 a 2008. RESULTADOS: A média de idade foi de 7,79 anos. Quanto ao sexo, encontramos 54,17 por cento do sexo masculino e 45,83 por cento do sexo feminino. Todos os pacientes foram submetidos a quimioterapia (QT), sendo que 62,5 por cento destes também realizaram radioterapia (RT) e 16,67 por cento foram submetidos a cirurgia. Dos 24 pacientes, 8 (33,3 por cento) foram a óbito, 6 (25 por cento) encontravam-se livres de neoplasia e 2 ( 8,3 por cento) apresentaram recidiva do tumor. CONCLUSÃO: O RMS de cabeça e pescoço frequentemente se apresenta com sintomas inespecíficos. Terapia multimodal individualizada deve ser realizada, incluindo cirurgia, quimioterapia e radioterapia.
Rhabdomyosarcoma (RMS) is a malignant tumor of soft tissues, more common in childhood, mainly located in the head and neck. It presents varied clinical and biological behavior and requires individualized management. AIM: To describe information on patients with head and neck RMS diagnosed and treated in a hospital, and to compare them to results in the literature. Study design: Descriptive and retrospective. MATERIALS AND METHODS: A retrospective analysis of data from 24 patients with head and neck rhabdomyosarcoma diagnosed and treated in a hospital from 1994 to 2008. RESULTS: The mean age was 7.79 years. According to gender, 54.17 percent were males and 45.83 percent were female. All patients underwent chemotherapy (CT), 62.5 percent of them also underwent radiotherapy (RT) and 16.67 percent were submitted to surgery. Of the 24 patients, 8 (33.3 percent) died, 6 (25 percent) were found free of neoplasia and 2 (8.3 percent) experienced tumor recurrence. CONCLUSION: The RMS of the head and neck often presents with nonspecific symptoms. Individualized multimodal therapy should be performed for these patients, including surgery, chemotherapy and radiotherapy.
Asunto(s)
Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Adulto Joven , Neoplasias de Cabeza y Cuello , Rabdomiosarcoma , Terapia Combinada/métodos , Supervivencia sin Enfermedad , Neoplasias de Cabeza y Cuello/diagnóstico , Neoplasias de Cabeza y Cuello/mortalidad , Neoplasias de Cabeza y Cuello/terapia , Estudios Retrospectivos , Rabdomiosarcoma/diagnóstico , Rabdomiosarcoma/mortalidad , Rabdomiosarcoma/terapia , Adulto JovenRESUMEN
BACKGROUND AND AIMS: Rhabdomyosarcoma (RMS) is a pediatric tumor whose classification is based on histological criteria according to two main subgroups, embryonal RMS (ERMS) and alveolar RMS (ARMS). The majority but not all ARMS carry the specific PAX3(7)/FKHR translocation. The type of translocation in patients with ARMS defines the prognosis. METHODS: We retrospectively analyzed 30 cases of ARMS in Mexican patients and evaluated the fusion status of the genes using RT-PCR and fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded tissues (FFPET). RESULTS: From 25 samples (83%) with optimal RNA quality, RT-PCR revealed 15 cases (50%) with the t(2;13)/PAX3-FKHR. Only one case (3%) was positive to t(1;13)/PAX7-FKHR and nine cases (30%) were fusion-negative. Correspondingly, using FISH, the t(2;13)/PAX3-FKHR was found positive in 19 cases (63.5%), one case (3%) revealed the t(1;13)/PAX7/FKHR and ten cases (33.5%) were fusion-negative by this method. Five cases were not evaluable by RT-PCR but recovered by FISH. Only four of the total revealed t(2;13); the other was fusion-negative. CONCLUSIONS: FISH technique is more sensitive when FFPET is used to describe the chromosomal translocation of ARMS. These Latino patients showed an association of the t(2;13) in older patients (mean: 9 years) and negative translocation in younger patients (mean: 4 years) (p <0.05). Both t(2;13) and negative-fusion were present in patients with clinical stages III and IV (p <0.05). There was a nonsignificant trend of t(2;13) to lower overall survival than negative-fusion status.
Asunto(s)
Hibridación Fluorescente in Situ/métodos , Proteínas Recombinantes de Fusión/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Rabdomiosarcoma/genética , Niño , Formaldehído , Humanos , Estimación de Kaplan-Meier , México , Adhesión en Parafina , Estudios Retrospectivos , Rabdomiosarcoma/clasificación , Rabdomiosarcoma/mortalidad , Rabdomiosarcoma/patologíaRESUMEN
We identified all children enrolled in the Intergroup Rhabdomyosarcoma Study Group-IV with neurofibromatosis type I (NF1) and rhabdomyosarcoma. Among 1025 eligible patients, 5 (0.5 %) had NF1. Three children had relapses, two of whom died of progressive disease. Patients with NF1 and rhabdomyosarcoma should be treated with intensive contemporary therapy protocols.
Asunto(s)
Neoplasias Primarias Secundarias/epidemiología , Neurofibromatosis 1/epidemiología , Rabdomiosarcoma/patología , Adolescente , Canadá/epidemiología , Niño , Preescolar , Supervivencia sin Enfermedad , Femenino , Humanos , Lactante , Masculino , Neoplasias Primarias Secundarias/mortalidad , Neoplasias Primarias Secundarias/patología , Neurofibromatosis 1/mortalidad , Neurofibromatosis 1/patología , Prevalencia , Neoplasias de la Próstata/epidemiología , Neoplasias de la Próstata/patología , Estudios Retrospectivos , Rabdomiosarcoma/epidemiología , Rabdomiosarcoma/mortalidad , Tasa de Supervivencia , Neoplasias de la Vejiga Urinaria/epidemiología , Neoplasias de la Vejiga Urinaria/patologíaRESUMEN
El rabdomiosarcoma de vejiga es un tumor de partes blandas raro en los adultos y más frecuente en los niños. Se realiza una revisión de la bibliografía y presentación de un caso(AU)
Asunto(s)
Humanos , Masculino , Anciano , Rabdomiosarcoma/clasificación , Rabdomiosarcoma/mortalidad , Rabdomiosarcoma/tratamiento farmacológico , Rabdomiosarcoma/terapia , Neoplasias de la Vejiga Urinaria , Estadificación de NeoplasiasRESUMEN
Objetivo. Establecer la relación entre mortalidad y las características clínicas y anatomo-patológicas de niños con rabdomiosarcoma. Diseño. Revisión retrospectiva de las características clínico-patológicas relacionándolas con la mortalidad de los niños con rabdomiosarcoma atendidos de 1963 a 1985. Marco de referencia. Servicio de Oncología. Hospital de Pediatría, Centro Médico Nacional, Instituto Mexicano del Seguro Social. Pacientes. Muestra secuencial de 126 niños con rabdomiosarcoma observados durante un periodo no menor de cinco años. Mediciones y resultados. La mortalidad fue menor en las localizaciones orbitarias (14.8 por ciento) que en el resto (42.4 por ciento) (P<0.01) y mayor en las retroperitoneales y en el tronco (62.5 por ciento cada uno) que en otro sitio (P<0.02). Se tuvieron 18 defunciones en 24 pacientes con enfermedad diseminada y 23 de 93 con padecimiento localizado o locorregional (P<0.01). Aunque la mortalidad fue más baja en las subvariedades no alveolares (34 por ciento) que en las alveolares (46 por ciento), no se encontró diferencia estadística entre las subvariedades histológicas. La mortalidad fue similar entre diversos grupos de edad de niños. Conclusiones. Se encontraron como variables que influyen significativamente en la mortalidad, a la localización del tumor primario y a la extensión inicial de la enfermedad. Porcentualmente la mortalidad fue menor en las subvariedades no alveolares pero con P<0.05. La edad de los pacientes no influyó en la mortalidad
Asunto(s)
Recién Nacido , Lactante , Preescolar , Niño , Humanos , Neoplasias de Cabeza y Cuello/mortalidad , Neoplasias de Cabeza y Cuello/patología , Pronóstico , Rabdomiosarcoma/mortalidad , Rabdomiosarcoma/patología , SobrevivientesRESUMEN
Se estudian 200 casos de sarcomas de partes blandas que abarcan las variedades histológicas más frecuentes inscriptas en el Instituto Nacional de Oncología y Radiobiología durante los años 1963 a 1972 conjuntamente con la información obtenida por el Registro Nacional del Cáncer acerca de estos tumores y los trabajos publicados por nuestro centro desde 1963 a 1983 para analizar el comportamiento de esta enfermedad, y llegar a la conclusión de que los tumores malignos de las partes blandas son lesiones que se observan con relativa poca frecuencia, pero su incidencia y mortalidad han tenido tendencia a elevarse constantemente en los últimos años. La enfermedad se observa en todas las edades de preferencia por encima de los 30 años, y predomina en el sexo masculino, y son los tipos histológicos fundamentales: fibrosarcoma, liposarcoma y rabdomiosarcoma. Los miembros inferiores ocupan el primer lugar en cuanto a localización, pero la enfermedad está muy estrechamente relacionada con la Histología. El sinoviosarcoma y el neurofibrosarcoma se comportan como las lesiones más agresivas por su alto poder de metastización y su elevado índice de metástasis pulmonares y ganglionares. El tratamiento más adecuado es el que contempla el empleo de las armas terapéuticas fundamentales: Cirugía, radiaciones y poliquimioterapia como un todo sincrónico, ajustable, donde se aplica cada una de ellas en el momento requerido. La supervivencia global de 5 años fue del 39
, que está en dependencia con la extensión y localización de la lesión, la edad de presentación, el tipo histológico, el grado de diferenciación tumoral y el tratamiento empleado, como factores fundamentales (AU)
Asunto(s)
Recién Nacido , Lactante , Preescolar , Niño , Adolescente , Adulto , Persona de Mediana Edad , Anciano , Humanos , Masculino , Femenino , HISTORIA DE LA MEDICINA DEL SIGLO 20 , Neoplasias de los Tejidos Blandos/epidemiología , Sarcoma/epidemiología , Fibrosarcoma/epidemiología , Fibrosarcoma/mortalidad , Liposarcoma/epidemiología , Liposarcoma/mortalidad , Neoplasias de los Tejidos Blandos/mortalidad , Rabdomiosarcoma/epidemiología , Rabdomiosarcoma/mortalidad , CubaRESUMEN
Se estudian 200 casos de sarcomas de partes blandas que abarcan las variedades histológicas más frecuentes inscriptas en el Instituto Nacional de Oncología y Radiobiología durante los años 1963 a 1972 conjuntamente con la información obtenida por el Registro Nacional del Cáncer acerca de estos tumores y los trabajos publicados por nuestro centro desde 1963 a 1983 para analizar el comportamiento de esta enfermedad, y llegar a la conclusión de que los tumores malignos de las partes blandas son lesiones que se observan con relativa poca frecuencia, pero su incidencia y mortalidad han tenido tendencia a elevarse constantemente en los últimos años. La enfermedad se observa en todas las edades de preferencia por encima de los 30 años, y predomina en el sexo masculino, y son los tipos histológicos fundamentales: fibrosarcoma, liposarcoma y rabdomiosarcoma. Los miembros inferiores ocupan el primer lugar en cuanto a localización, pero la enfermedad está muy estrechamente relacionada con la Histología. El sinoviosarcoma y el neurofibrosarcoma se comportan como las lesiones más agresivas por su alto poder de metastización y su elevado índice de metástasis pulmonares y ganglionares. El tratamiento más adecuado es el que contempla el empleo de las armas terapéuticas fundamentales: Cirugía, radiaciones y poliquimioterapia como un todo sincrónico, ajustable, donde se aplica cada una de ellas en el momento requerido. La supervivencia global de 5 años fue del 39%, que está en dependencia con la extensión y localización de la lesión, la edad de presentación, el tipo histológico, el grado de diferenciación tumoral y el tratamiento empleado, como factores fundamentales
Asunto(s)
Recién Nacido , Lactante , Preescolar , Niño , Adolescente , Adulto , Persona de Mediana Edad , Humanos , Masculino , Femenino , Historia del Siglo XX , Sarcoma/epidemiología , Neoplasias de los Tejidos Blandos/epidemiología , Cuba , Fibrosarcoma/epidemiología , Fibrosarcoma/mortalidad , Liposarcoma/epidemiología , Liposarcoma/mortalidad , Rabdomiosarcoma/epidemiología , Rabdomiosarcoma/mortalidad , Neoplasias de los Tejidos Blandos/mortalidadAsunto(s)
Humanos , Masculino , Femenino , Lactante , Preescolar , Niño , Adolescente , Adulto , Rabdomiosarcoma/diagnóstico , Neoplasias del Cuello Uterino/diagnóstico , Neoplasias de la Vejiga Urinaria/diagnóstico , Rabdomiosarcoma/radioterapia , Rabdomiosarcoma/cirugía , Enfermedades Auditivas Centrales/complicaciones , Rabdomiosarcoma/mortalidad , Quimioterapia Combinada , Distribución por Edad y Sexo , Distribución por EtniaRESUMEN
The present work includes the review of eight cases of sarcoma botryoides of the vagina, seen at the Hospital Infantil de Mexico, between 1943 and 1972. It is proved that it is an uncommon tumor, which appears between the first and five years of age. The more frequent symptoms were the vaginal hemorrhage, abdominal mass and the visualization of the tumor in the vaginal introit. The evolution was fatal in the 100% of the cases, between 6 and 12 months after the first consultation, whether the treatment given was surgical, with X-rays or chemical agents. The biopsy was definitive in all cases, to corroborate the clinic diagnosis and the cystoscopy, cystogram, vaginoscopy, excretory urography and venocavography were important aids for the diagnosis. The preliminary diagnosis must be done by the general pediatrician in the presence of suggestive symptoms of sarcoma botryoides of the vagina and the radical treatment must be done immediately to obtain some possibility of life.